	Diagnostic challenge of delayed immune-related hepatitis during zongertinib treatment after nivolumab plus ipilimumab in a 52-year-old man with HER2-mutant non-small cell lung cancer: a case report. Transl Lung Cancer Res Oba T, Shiohira S, Machida Y, Nakatani D, Akasaka K, Amano M, Matsushima H. PMID: 42999648 [PubMed]
	Efficacy and safety of stereotactic body radiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis. Transl Lung Cancer Res Ji P, Zhao Z, Tang X, Dai Z, Mi X, Xing Y, Xie Y, Liao W, Zhang X, Pu Q. PMID: 42999638 [PubMed]
	Real-world treatment patterns in stage IB-IIIC non-small cell lung cancer in China: the KEY-RAISE study. Transl Lung Cancer Res Zhong H, Yan S, Zeng J, Ba Y, Mei J, Sun D, Fu X, Liang W, Fu J, Gu K, Xiao S, Li M, Zheng L, Peng S, Wu N. PMID: 42999634 [PubMed]
	Single-cell and spatial transcriptome analyses unveil that MYH11 links stemness to immunotherapy resistance in non-small cell lung cancer. Transl Lung Cancer Res Xie Y, Xue Y, Lai D, Zhang X, Li G, Zhou Q. PMID: 42999620 [PubMed]
	Antibody-drug conjugates in the perioperative treatment of resectable non-small cell lung cancer: a narrative review of research advances and prospects. Transl Lung Cancer Res Xiong Y, Sun L, Peng Y. PMID: 42999616 [PubMed]
	Functional decline at progression after durvalumab in stage III non-small cell lung cancer: prognostic impact and treatment patterns in a multicenter retrospective cohort study. Transl Lung Cancer Res Lisik-Habib M, Smó, Stando R, Chmielewski G, Bilski M, Galwas K, Tworek D, Puskulluoglu M, Roman A, Terlecka-Maciejewska M, Fijuth J, Kuncman . PMID: 42999612 [PubMed]
	Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study. Transl Lung Cancer Res Wang J, Zhi X, Chen J, Zhang B, Lan H, Jiao F, Liu Y, Wu F, Yu J, Li A, Ji C, Fang Q, Ren S. PMID: 42999610 [PubMed]
	Perioperative treatment for resectable non-small cell lung cancer harboring EGFR exon 20 insertion mutations: a narrative review from advanced-stage evidence to whole-course precision management. Transl Lung Cancer Res Li Z, Han Y, Zhong W, Li H. PMID: 42999608 [PubMed]
	Real-world outcomes of neoadjuvant targeted therapy in resectable epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective study. Transl Lung Cancer Res Li J, Zhang Y, Gao J, Deng H, Luo Z, Ma X, Xie M, Xue X. PMID: 42999602 [PubMed]
	Subtype-associated clinicopathological and tumor immune microenvironment heterogeneity in primary EGFR T790M compound-mutant lung adenocarcinoma: a retrospective cohort study. Transl Lung Cancer Res Lin Y, Ye Z, Wu S, Wang B, Wang L, Gao L, Jiao D, Li W, Ying J. PMID: 42999423 [PubMed]
	Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study. Transl Lung Cancer Res Kim IA, Kim H, Hur JY, Kim WS, Kim YW, Lee SA, Hwang JJ, Lee KY. PMID: 42999407 [PubMed]
	Development and validation of a deep learning model integrating (18)F-FDG PET/CT radiomics and clinical features to predict major pathological response in non-small cell lung cancer patients receiving chemoimmunotherapy. Transl Lung Cancer Res Li A, Mao ZH, Wang HL, Wang Y, Fu QH, Feng WC, Chen Y, Hu YT, Liu ZH, Zhong WZ, Jiang L, Jiang BY. PMID: 42999401 [PubMed]
	Novel 4-Anilinopyrimidine-N-Acylhydrazone derivatives as dual EGFR(WT)/VEGFR-2 tyrosine kinase inhibitors against non-small cell lung Cancer: Design, synthesis, biological evaluation, and computational studies. Bioorg Chem Ibrahim TH, Kadry HH, Mohamed KO, Loksha YM, Nasrallah RS, Nemr MTM. PMID: 42998399 [PubMed - as supplied by publisher]
	Corrigendum to 'Lung Cancer Screening in Asia: An Expert Consensus Report' [Journal of Thoracic Oncology Volume 18 Issue 10 (2023) 1303-1322]. J Thorac Oncol Chi-Leung Lam D, Liam CK, Andarini S, Park S, Tan DSW, Singh N, Jang SH, Vardhanabhuti V, Ramos AB, Nakayama T, Nhung NV, Ashizawa K, Chang YC, Tscheikuna J, Van CC, Chan WY, Lai YH, Yang PC. PMID: 42998071 [PubMed - as supplied by publisher]
	Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors. Cancer Med Deng X, Wu D, Ni L, Li W, Liu Z, Liu J, Liu J. PMID: 42998017 [PubMed - indexed for MEDLINE]
	(18)F-FDG PET/CT Habitat Radiomics for Predicting Epidermal Growth Factor Receptor Mutation Status in Locally Advanced Non-small Cell Lung Cancer: A Multicenter Study. Technol Cancer Res Treat Lian H, Deng H, Zheng J, Ji Y, Wang Y. PMID: 42997983 [PubMed - indexed for MEDLINE]
	Immunotherapy maintenance in extensive-stage small-cell lung cancer: a real-world retrospective study. Transl Cancer Res Lin X, Lin N, Zhang Q, Zhang S, Liang X, Wang B, Dong Z, Tong Y, Zhang Y, Ma X, Liao H. PMID: 42997909 [PubMed]
	A DualDrop-Gated Transformer model for predicting bone metastasis in Asian patients with non-small cell lung cancer: a real-world study with external validation. Quant Imaging Med Surg Wang X, Yu H, Shen Y, Qian Q, Gao X, Xie Z, Gu J, Tao G, Zhang Z, Li S, Li J, Nie K, Sun L, Zhu L. PMID: 42997782 [PubMed]
	Predicting immunotherapy response in patients with non-small cell lung cancer: superior performance of a positron emission tomography radiomics-based stacking ensemble model. Quant Imaging Med Surg Zhang L, Zeng Z, Sheng P, Peng J, Zhang X, Xu C, Wang J. PMID: 42997730 [PubMed]
	Development and validation of a phase-stable computed tomography radiomics model for brain metastasis risk stratification in non-small cell lung cancer. Transl Cancer Res Li Z, Xia X, Chen J, Du Y, Zhou J, Zhu Y, Li X, Wan Q. PMID: 42997722 [PubMed]

Articles 1 - 20 / 163374

Page 1 of 8169



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy